Dergiler / Şişli Etfal Hastanesi Tıp Bülteni / 2020 / Cilt: 54 - Sayı: 4

Pheochromocytoma and Paraganglioma: From Treatment to Follow-up

Sayfa
391–398
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In thisreview, it was aimed to evaluate the pre-, per and post-operative management, curative and palliative surgical management, andpostoperative outcomes and follow-up of the patients with PPGLs.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors arising from chromaffin cells in the adrenalmedulla, sympathetic or parasympathetic ganglia.
📊
Temel Bulgular & Veri:Postoperative major complications are hypotension and rebound hypoglycemia, and patients should be followed closely for 24-48 hours.
💡
Sonuç & Katkı:In thisreview, it was aimed to evaluate the pre-, per and post-operative management, curative and palliative surgical management, andpostoperative outcomes and follow-up of the patients with PPGLs.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors arising from chromaffin cells in the adrenalmedulla, sympathetic or parasympathetic ganglia. Currently, the only curative treatment option of pheochromocytomas/paraganglioma (PPGL) is surgical resection. Surgery aims to eliminate both risks of hypersecretion and tumor growth. The consequences ofhypersecretion should be carefully controlled with medical therapy before and during the surgery. Postoperative major complications are hypotension and rebound hypoglycemia, and patients should be followed closely for 24-48 hours. The choice of surgicalapproach is determined based on multiple factors, including germline genetic test results, the size of the tumor, body mass index,surgeon's experience, and the likelihood of malignancy. Primary tumor resection does not completely eliminate the risk of tumorpersistence and recurrence. Therefore, all patients with PPGL who are surgically treated should be followed for at least 10 years forrecurrent disease and new tumor formation. Although surgical resection is the only curative treatment for PPGLs, surgical treatment is palliative except for resectable locoregional metastases in metastatic disease or for isolated distant metastases. The purpose of palliative treatment is to reduce hormone secretion and prevent metastasis-related complications in a critical anatomicallocation Combined and alfa;- and beta- adrenergic blockade is usually applied in patients with PPGL preoperatively. Some patientsmay present with pheochromocytoma multisystem crisis, which is a life-threatening condition that can involve cardiovascular,pulmonary, neurological, gastrointestinal, renal, hepatic and metabolic systems. Pheochromocytoma crisis may be spontaneousor may present with the tumor manipulation, trauma, corticosteroids, beta-blockers, anesthetic drugs, and the stimulation of nonadrenal surgical stress. These patients should be considered as medical emergencies rather than surgical emergencies. In thisreview, it was aimed to evaluate the pre-, per and post-operative management, curative and palliative surgical management, andpostoperative outcomes and follow-up of the patients with PPGLs.

🔖

Bu Makaleye Atıf Yap

AYGÜN, N., ULUDAĞ, M. (2020). Pheochromocytoma and Paraganglioma: From Treatment to Follow-up. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 54 - Sayı: 4, 391–398. https://ajindex.com/articles/363683

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Tevosian SG, Ghayee HK. Pheochromocytomas and Paragangliomas. Endocrinol Metab Clin North Am 2019;48:727–50
  2. Patel D, Phay JE, Yen TWF, Dickson PV, Wang TS, Garcia R, et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Ann Surg Oncol 2020;27:1329–37
  3. Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul 2020;54:159–68
  4. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915–42
  5. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, et al; Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term followup of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 2016;174:G1–10
  6. Wiseman D, Lakis ME, Nilubol N. Precision Surgery for Pheochromocytomas and Paragangliomas. Horm Metab Res 2019;51:470– 82
  7. Groeben H, Walz MK, Nottebaum BJ, Alesina PF, Greenwald A, Schumann R, et al. International multicentre review of perioperative management and outcome for catecholamine-producing tumours. Br J Surg 2020;107:e170–8
  8. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med 2019;381:552–65
  9. Buitenwerf E, Osinga TE, Timmers HJLM, Lenders JWM, Feelders RA, Eekhoff EMW, et al. Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial. J Clin Endocrinol Metab 2020;105:2381–91
  10. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007;92:4069–79
  11. Wachtel H, Kennedy EH, Zaheer S, Bartlett EK, Fishbein L, Roses RE, et al. Preoperative Metyrosine Improves Cardiovascular Outcomes for Patients Undergoing Surgery for Pheochromocytoma and Paraganglioma. Ann Surg Oncol 2015;22 Suppl 3:S646–54
  12. Scholten A, Cisco RM, Vriens MR, Cohen JK, Mitmaker EJ, Liu C, et al. Pheochromocytoma crisis is not a surgical emergency. J Clin Endocrinol Metab 2013;98:581–91
  13. Newell KA, Prinz RA, Pickleman J, Braithwaite S, Brooks M, Karson TH, et al. Pheochromocytoma multisystem crisis. A surgical emergency. Arch Surg 1988;123:956–9
  14. Sauneuf B, Chudeau N, Champigneulle